NASDAQ:NMTC NeuroOne Medical Technologies (NMTC) Stock Price, News & Analysis $0.66 +0.02 (+2.32%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeuroOne Medical Technologies Stock (NASDAQ:NMTC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NMTC alerts:Sign Up Key Stats Today's Range$0.69▼$0.6950-Day Range$0.43▼$0.6752-Week Range$0.40▼$1.39Volume10,734 shsAverage Volume186,123 shsMarket Capitalization$33.13 millionP/E RatioN/ADividend YieldN/APrice Target$1.45Consensus RatingBuy Company OverviewNeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Read More… NeuroOne Medical Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreNMTC MarketRank™: NeuroOne Medical Technologies scored higher than 36% of companies evaluated by MarketBeat, and ranked 568th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNeuroOne Medical Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeuroOne Medical Technologies has only been the subject of 1 research reports in the past 90 days.Read more about NeuroOne Medical Technologies' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroOne Medical Technologies is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroOne Medical Technologies is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroOne Medical Technologies has a P/B Ratio of 21.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NeuroOne Medical Technologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.45% of the float of NeuroOne Medical Technologies has been sold short.Short Interest Ratio / Days to CoverNeuroOne Medical Technologies has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroOne Medical Technologies has recently increased by 5.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroOne Medical Technologies does not currently pay a dividend.Dividend GrowthNeuroOne Medical Technologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.45% of the float of NeuroOne Medical Technologies has been sold short.Short Interest Ratio / Days to CoverNeuroOne Medical Technologies has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroOne Medical Technologies has recently increased by 5.77%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for NMTC on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, NeuroOne Medical Technologies insiders have bought 2,593.48% more of their company's stock than they have sold. Specifically, they have bought $150,000.00 in company stock and sold $5,569.00 in company stock.Percentage Held by InsidersOnly 8.90% of the stock of NeuroOne Medical Technologies is held by insiders.Percentage Held by InstitutionsOnly 16.07% of the stock of NeuroOne Medical Technologies is held by institutions.Read more about NeuroOne Medical Technologies' insider trading history. Receive NMTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroOne Medical Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address NMTC Stock News HeadlinesNeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate SecretaryJune 3, 2025 | globenewswire.comNeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025May 29, 2025 | uk.finance.yahoo.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.June 18, 2025 | Brownstone Research (Ad)NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025May 29, 2025 | globenewswire.comEarnings call transcript: NeuroOne Medical beats EPS expectations in Q1 2025May 15, 2025 | uk.investing.comNeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q2 2025 Earnings Call TranscriptMay 14, 2025 | msn.comNeuroOne Medical Technologies Corp (NMTC) Q2 2025 Earnings Call Highlights: Revenue Surge and ...May 14, 2025 | uk.finance.yahoo.comNeuroOne expects FY25 revenue to reach $8M–$10M as OneRF platform advances and new FDA submission broadens pipelineMay 13, 2025 | msn.comSee More Headlines NMTC Stock Analysis - Frequently Asked Questions How have NMTC shares performed this year? NeuroOne Medical Technologies' stock was trading at $0.8259 at the beginning of 2025. Since then, NMTC shares have decreased by 21.3% and is now trading at $0.6499. View the best growth stocks for 2025 here. How were NeuroOne Medical Technologies' earnings last quarter? NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02. The company earned $1.39 billion during the quarter, compared to analyst estimates of $1.27 billion. NeuroOne Medical Technologies had a negative net margin of 75.41% and a negative trailing twelve-month return on equity of 334.64%. Read the conference call transcript. Who are NeuroOne Medical Technologies' major shareholders? NeuroOne Medical Technologies' top institutional investors include Goldman Sachs Group Inc. (0.21%) and Cambridge Investment Research Advisors Inc. (0.17%). Insiders that own company stock include Ronald W Mcclurg, Mark Christianson and Christopher Volker. View institutional ownership trends. How do I buy shares of NeuroOne Medical Technologies? Shares of NMTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroOne Medical Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroOne Medical Technologies investors own include Schwab US Large-Cap ETF (SCHX), NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), Ford Motor (F), Meta Platforms (META) and Plug Power (PLUG). Company Calendar Last Earnings5/13/2025Today6/17/2025Next Earnings (Estimated)8/13/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryMedical Equipment Current SymbolNASDAQ:NMTC CIK1500198 Webwww.originalsourcemusic.com Phone(952) 426-1383FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$1.45 High Stock Price Target$1.45 Low Stock Price Target$1.45 Potential Upside/Downside+123.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.32 million Net Margins-75.41% Pretax Margin-75.40% Return on Equity-334.64% Return on Assets-124.42% Debt Debt-to-Equity RatioN/A Current Ratio2.13 Quick Ratio1.09 Sales & Book Value Annual Sales$3.45 million Price / Sales9.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book21.66Miscellaneous Outstanding Shares49,820,000Free Float45,384,000Market Cap$32.38 million OptionableOptionable Beta0.63 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:NMTC) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Shocking Link Between A.I. and Your MoneyThe AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroOne Medical Technologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroOne Medical Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.